PRP injection, shoulder soreness, and a careful choice

PRP helps some shoulders but not others

Some people feel better after PRP, while others notice little change. Studies can’t predict one result for every cause of shoulder trouble. A worn joint, a sore tendon, and a torn tendon aren’t the same problem. Ask whether the studies included people with the problem found during your exam.

PRP doesn’t come with promised relief.

PRP used during surgery is not office care

During surgery, PRP may be placed around a tendon that has just been repaired. Office care places it near a sore area without an operation. A surgery study can’t tell you how office care will feel or whether it will ease soreness. Ask which kind of care each study examined.

The difference matters.

PRP cannot promise repair or relief

PRP can’t reverse arthritis or promise that a torn tendon will grow back. It may be considered after simpler care hasn’t brought enough relief. Your exam, general health, current medicines, and earlier care all need to be discussed. The clinician should explain why it may fit and why it may not.

Hear the limits before money changes hands.

The clinic sets the full PRP shoulder cost

There isn’t one published price that fits every Glendale visit. Ask for a written charge covering the exam, blood preparation, ultrasound used to aim the treatment, and later visits. Find out whether more care would bring another bill. Insurance usually doesn’t pay for shoulder PRP.

Read the quote before choosing a date.

Clinics may prepare PRP in different ways

Clinics may prepare PRP with different amounts of platelets. They may also place it in different parts of the shoulder. Ask how the clinic makes its concentrated PRP and where it will be placed. Also ask whether an ultrasound will help aim it. If you don’t understand the answer, wait before paying.

You’re buying a particular service, not just a name.

Sources

1. The August 2025 AAOS Evidence-Based Clinical Practice Guideline on Management of Rotator Cuff Injuries issued 25 recommendations and 4 consensus statements. Among its updates it clearly RESTRICTS the use of platelet-rich plasma and marrow stimulation in rotator cuff repair, limits prolotherapy in full-thickness tears, establishes CT as an adjunctive imaging modality, and endorses early mobilization after repair of small-to-medium tears.

   Ye Y, et al. — [Interpretation of the 2025 American Academy of Orthopaedic Surgeons (AAOS) on Management of Rotator Cuff Injuries Evidence-Based Clinical Practice Guideline].. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2026. DOI: 10.7507/1002-1892.202511084.

2. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

3. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development study. There is no Medicare national coverage for PRP in shoulder osteoarthritis or rotator cuff disease, which is why these injections are billed to the patient directly.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

4. A 2026 meta-analysis of 10 randomized trials (n=591) found PRP and corticosteroid indistinguishable at 3-6 weeks and 3 months, with PRP pulling ahead at 6 months: ASES +10.8 (95% CI 4.71-16.80), Constant-Murley +10.7 (1.21-20.27) and VAS pain -0.8 (-1.45 to -0.18), plus fewer adverse events (RR 0.66, 0.44-0.99). The authors describe the benefit as statistically significant but CLINICALLY MODEST.

   Yuwarungsikul C, et al. — Platelet-rich plasma provides modest but durable functional benefit over corticosteroid for rotator cuff tendinopathy: A systematic review and meta-analysis of randomized controlled trials.. Knee Surg Sports Traumatol Arthrosc, 2026. DOI: 10.1002/ksa.70416.

5. A meta-analysis of nine randomized trials (469 patients) found corticosteroid superior to PRP in the SHORT term on Constant, Simple Shoulder Test and ASES scores, no difference at mid-term, and PRP superior in the LONG term on Simple Shoulder Test and ASES. The authors state explicitly that none of these differences reached the minimal clinically important difference.

   Peng Y, et al. — Comparison of the effects of platelet-rich plasma and corticosteroid injection in rotator cuff disease treatment: a systematic review and meta-analysis.. J Shoulder Elbow Surg, 2023. DOI: 10.1016/j.jse.2023.01.037.

6. A meta-analysis of nine randomized trials (n=629) in partial-thickness rotator cuff tears and tendinopathy found statistically significant SHORT-term (6 +/- 1 months) PRP effects on pain (MD -1.56), Constant-Murley (+16.48) and SPADI (-18.78), but NO long-term effect on pain or function except Constant-Murley - i.e. the benefit may not last.

   Xiang XN, et al. — Conservative treatment of partial-thickness rotator cuff tears and tendinopathy with platelet-rich plasma: A systematic review and meta-analysis.. Clin Rehabil, 2021. DOI: 10.1177/02692155211011944.

7. A 2026 meta-analysis of 21 studies (1,279 patients) found leukocyte-poor PRP augmentation at rotator cuff repair reduced structural retear risk (overall RR 0.74, 95% CI 0.55-0.99), with the benefit clearest in medium-sized tears (RR 0.68). Patient-reported outcomes did NOT improve consistently, publication-bias diagnostics indicated small-study effects (Egger p=0.017), and trim-and-fill adjustment moved the estimate to a non-significant RR 0.91 (0.69-1.19).

   Dunivan Q, et al. — Leukocyte-poor platelet-rich plasma reduces retear risk after arthroscopic rotator cuff repair: a meta-analysis with mechanistic and economic evaluation.. J Shoulder Elbow Surg, 2026. DOI: 10.1016/j.jse.2026.02.018.

8. A meta-analysis with a formal cost-effectiveness analysis found PRP did not reduce retear risk across all tear sizes (RR 0.87, 95% CI 0.67-1.12) but did for small and medium tears under 3 cm (RR 0.60, 0.37-0.97; number needed to treat 14). At an incremental cost-effectiveness ratio of US$127,893 per quality-adjusted life year, the authors concluded PRP was NOT cost-effective even where it worked.

   Vavken P, et al. — Platelet-Rich Plasma Reduces Retear Rates After Arthroscopic Repair of Small- and Medium-Sized Rotator Cuff Tears but Is Not Cost-Effective.. Am J Sports Med, 2015. DOI: 10.1177/0363546515572777.

9. A current-concepts review of non-operative management of shoulder osteoarthritis states plainly that biologics such as PRP, bone marrow aspirate concentrate and mesenchymal stem cells 'are helpful in decreasing shoulder pain but neither stopping the progression nor improving OA', and that first-line care is physical therapy with NSAIDs.

   Yamamoto N, et al. — Non-operative management of shoulder osteoarthritis: Current concepts.. J ISAKOS, 2023. DOI: 10.1016/j.jisako.2023.06.002.